Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1420-1428

  Sun, Yuan ^a   Wu, Jack ^a   Aboukameel, Amro ^a   Banerjee, Sanjeev ^a   Arnold, Alan A ^a   Chen, Jianyong ^b   Nikolovska Coleska, Zaneta ^b   Lin, Yanqiong ^c   Ling, Xiaolan ^c   Yang, Dajun ^c   Wang, Shaomeng ^b   Al Katib, Ayad ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Ascenta Therapeutics   (United States)

Author keywords

Animal model; Apoptosis; Bcl 2 family of protein; Chemotherapy; Diffuse large cell lymphoma; Small molecule inhibitors; Toxicity

Indexed keywords

APOGOSSYPOLONE; GOSSYPOL; PROTEIN BCL 2; UNCLASSIFIED DRUG; APOGOSSYPOL; CASPASE 3; CASPASE 9; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL X; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; ANIMAL; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; GENETICS; IC 50; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHASE 2 CLINICAL TRIAL; TEMPERATURE; TIME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASE 9; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; GOSSYPOL; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; MOLECULAR STRUCTURE; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; TEMPERATURE; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52149098982     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.9.6430     Document Type: Article

References (47)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphoma: clinical features of the major histological subtypes. J Clin Oncol 1998; 6:278-95.
2. Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histocytic lymphoma with cyclonphosphamide, Adriamycin, vincristine and prednisone (CHOP). Cancer 1978; 42:1705-10.
3. collins-Burow B, Santos ES. Ritaximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2007; 7:257-73.
4. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang SM, Al-Katib AM. Preclinical studies of TW-37, a new non-peptide small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007; 13:2226-35.
5. L [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4:13-21.
6. Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Outcome of elderly patients with aggressive non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004; 45:1391-4.
7. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of retuximab. Anticancer Drugs 2002; 13:3-10.
8. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7:541-6.
9. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998; 8:324-30.
10. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281:1322-6.
11. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17:3225-36.
12. Fernandez-Luna JL. Apoptosis regulators as target for cancer therapy. ClinTransl Oncol 2007; 9:555-62.
13. Zhang L, Ming L, Yu J. BH3 mimetic to improve cancer therapy; mechanisms and examples. Drug Resist Update 2007; 10:207-17.
14. Enings KE, Wiggins CM, Cook SJ. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007; 6:2236-40.
15. Mohammad RM, Anshu G, Goustin AS. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in Cancer. Recent Patents on Anti-Cancer Drug Discovery 2008; 3:25-36.
16. Roset R, Ortet L, Gil-Gomez G. Role of Bcl-2 family members on apoptosis: what we have learned from knock-out mice. Front Biosci 2007; 12:4722-30.
17. Verma YK, Gangenahall GU, Singh VK, Gupta P, Chandra R, sharma RK, Raj HG. Cell death regulation by B-cell lymphoma proteins. Apoptosis 2006; 11:459-71.
18. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108:153-64.
19. Oltuai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-19.
20. Buolamwini JK. Novel anticancer drug discovery. Current Opin Chem Biol 1999; 3:500-9.
21. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang SM. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44:4313-24.
22. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97:7124-9.
23. Muchmore SW, Sattle M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death. Nature 1996; 381:335-41.
24. Aritomi M, Kunishima N, Inohara N, Ishibashi Y, Ohta S, Morikawa K. Implications for the function of the Bcl-2 protein family. J Biol Chem 1997; 272:27886-92.
25. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. Structure of Bcl-XL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275:983-6.
26. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, Dipaola RS, Rosen N, Scher HI. Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8:679-83.
27. Piche A, Grim J, Rancourt C, Gómez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cell line MCF-7. Cancer Res 1998; 58:2134-40.
28. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000; 60:1498-502.
29. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005; 435:677-81.
30. Al-katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin1 downregulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998; 4:1305-14.
31. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of Bryostatin 1 to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6:4950-6.
32. Wang G, Nikolovska-Colesk Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang SM. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49:6139-42.
33. Smith PK, Krohn RI, Hermanosn GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
34. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048). Blood 2008; 111:3211-19.
35. Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-108.
36. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor Obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109:5430-8.
37. Kaneko M, Nakashima T, Uosaki Y, Hara M, Ikeda S, Kanda Y. Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. Bioorg Med Chem Lett 2001; 11:887-90.
38. L that are not the classic BH3 binding cleft. J Mol Biol 2006; 364:536-49.
39. Chen M, Xing D, Chen T, Zhang L. Bim involvement in Bax activation during UV irradiation-induced apoptosis. Biochem Biophys Res Commun 2007; 358:559-65.
40. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 1994; 54:1707-14.
41. Shelley MD, Hartley L, Groundwater PW, Fish RG. Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs 2000; 11:209-16.
42. Teng CS. Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Contraception 1995; 52:389-95.
43. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, Characterization, and Structure-Activity Relationships Studies of Proapoptotic Polyphenols Targeting B-Cell Lymphocyte/Leukemia-2 Proteins. J Med Chem 2003; 46:4259-64.
44. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 1993; 70:62-7.
45. Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad RM. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:313-7.
46. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NFkappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005; 56:46-54.
47. Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemther Pharmacol 2008; 61:63-73.